...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx
【24h】

Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx

机译:核苷酸切除修复核心基因的变体以及腹咽鳞状细胞癌复发的易感性

获取原文
获取原文并翻译 | 示例

摘要

Genetically determined capacity for NER may modulate both cancer risk and prognosis. Thus, we evaluated associations of seven selected variants in the NER core genes with recurrence risk in 658 squamous cell carcinoma of the oropharynx (SCCOP) patients treated principally by radiation. The seven polymorphisms in the core NER genes (XPC-rs2228000, XPC-rs2228001, XPD-rs1799793, XPD-rs13181, XPG-rs17655, ERCC1-rs3212986 and XPA-rs1800975) were genotyped using PCR-RFLP method and log-rank test and multivariable Cox models were used to evaluate the associations in both dominant and recessive genetic models. In a dominant model, we found that polymorphisms of XPC-rs2228000, XPD-rs1799793 and XPG-rs17655 were significantly associated with disease-free survival (log-rank, p = 0.014; p = 0.00008; p = 0.0007, respectively), and these polymorphisms were significantly associated with recurrence risk of SCCOP (hazard ratio (HR) = 1.6, 95% confidence interval (CI) 1.1-2.3 for XPC-rs2228000; HR = 0.4, 95% 0.3-0.6 for XPD-rs1799793 and HR = 0.5, 95% CI 0.4-0.8 for XPG-rs17655) after multivariable adjustment. Moreover, the borderline significant or significant associations were also found for these three polymorphisms in HPV16/18-positive SCCOP patients (HR = 1.6, 95% CI 1.0-4.1 for XPC-rs2228000; HR = 0.2, 95% CI 0.1-0.5 for XPD-rs1799793 and HR = 0.1, 95% CI 0.0-0.9 for XPG-rs17655). However, similarly significant associations were not found for these polymorphisms in a recessive model. These findings suggest that polymorphisms of XPC-rs2228000, XPD-rs1799793 and XPG-rs17655 in the NER core genes may contribute to recurrence risk of SCCOP, particularly HPV-positive SCCOP, in a dominant but not in a recessive model. However, validation of these results is warranted. What's new? Genetic variations in the nucleotide excision repair (NER) pathway may underlie interindividual differences in DNA repair capacity and thereby influence cancer risk and prognosis as well as susceptibility to genotoxicity associated with cancer therapy. This investigation lends support to that idea, revealing that variations in core NER genes may exert significant influence over disease-free survival and risk of disease recurrence in radiation-treated squamous cell carcinoma of the oropharynx (SCCOP) patients. The variants, which included XPC-rs2228000, XPD-rs1799793, and XPG-rs17655, may collectively serve as a marker of susceptibility to SCCOP recurrence, particularly in SCCOP patients who test positive for human papillomavirus.
机译:遗传确定的ner能力可以调节癌症风险和预后。因此,我们评估了七种选定的变体在NER核心基因中具有复发风险的七种选定变体的关联,其在原始辐射治疗的胃痛性患者的658例鳞状细胞癌中。基因分型使用PCR-RFLP方法和对数秩检验,七种多态性在核心基因(XPC-RS2228000,XPC-RS222280000,XPC-RS22228001,XPD-RS113181,XPD-RS312986和XPA-RS1800975)进行基因分型。使用多变量的Cox模型来评估占主导地位和隐性遗传模型中的关联。在主导模型中,我们发现XPC-RS2228000,XPD-RS1799793和XPG-RS17655的多态性与无病生存率显着相关(对数秩,P = 0.014; P = 0.00008; P = 0.0007)和这些多态性与SCCOP的复发风险显着相关(危险比(HR)= 1.6,95%置信区间(CI)1.1-2.3用于XPC-RS2228000; HR = 0.4,95%0.3-0.6用于XPD-RS1799793和HR =多变量调节后,0.5,95%CI 0.4-0.8为XPG-RS17655。此外,还发现了HPV16 / 18阳阳性SCCOP患者的这三种多态性(HR = 1.6,95%CI 1.0-4.1用于XPC-RS2228000; HR = 0.2,95%CI 0.1-0.5 XPD-RS1799793和HR = 0.1,95%CI 0.0-0.9用于XPG-RS17655)。然而,在隐性模型中没有发现类似的显着的关联。这些发现表明,XPC-RS2228000,XPD-RS1799793和XPG-RS17655中XPC-RS2228000,XPD-RS17655的多态性可能有助于SCCOP,特别是HPV阳性SCCOP的复发风险,以在显着的情况下,但不在隐性模型中。但是,保证了这些结果的验证。什么是新的?核苷酸切除修复(NER)途径的遗传变异可能提高DNA修复能力的细胞差异,从而影响癌症风险和预后以及与癌症治疗相关的遗传毒性的敏感性。该研究对该思想提供了支持,揭示核心基因的变化可能对胃痛药(SCCOP)患者的辐射治疗的鳞状细胞癌中的无病生存和疾病复发风险发挥着重大影响。包括XPC-RS2228000,XPD-RS1799793和XPG-RS17655的变体可以共同用作对SCCOP复发的易感性的标志物,特别是在对人乳头瘤病毒测试阳性的SCCOP患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号